Literature DB >> 28456566

Assessment of acute and chronic toxicity of doxorubicin in human induced pluripotent stem cell-derived cardiomyocytes.

Jochem Louisse1, Rob C I Wüst2, Francesca Pistollato3, Taina Palosaari3, Manuela Barilari3, Peter Macko3, Susanne Bremer3, Pilar Prieto3.   

Abstract

The present study assesses acute and chronic toxicity of doxorubicin in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), with the aim to obtain in vitro biomarkers that can be used as readouts to predict in vivo cardiotoxicity. Possible acute toxicity was investigated by assessing effects on the beating rate and the field potential duration (FPD) of doxorubicin-exposed cardiomyocytes by measuring electrical activity using multi-electrode array (MEA) analyses. No effects on the beating rate and FPD were found at concentrations up to 6μM, whereas at 12μM no electrical activity was recorded, indicating that the cardiomyocytes stopped beating. Acute and chronic effects of doxorubicin on mitochondria, which have been reported to be affected in doxorubicin-induced cardiotoxicity, were assessed using high content imaging techniques. To this end hiPSC-CMs were exposed to 150 or 300nM doxorubicin using both single dosing (3h and 2days) and repetitive dosing (3 times, of 2days each), including washout studies to assess delayed effects (assessment at day 14) and effects on cell number, mitochondrial density, mitochondrial membrane potential, mitochondrial superoxide levels and mitochondrial calcium levels were assessed. No effects of doxorubicin were found on mitochondrial density and mitochondrial superoxide levels, whereas doxorubicin reduced cell survival and slightly altered mitochondrial membrane potential and mitochondrial calcium levels, which was most profound in the washout studies. Altogether, the results of the present study show that concentrations of doxorubicin in the micromolar range were required to affect electrical activity of hiPSC-CMs, whereas nanomolar concentrations already affected cell viability and caused mitochondrial disturbances. Integration of these data with other in vitro data may enable the selection of a series of in vitro biomarkers that can be used as readouts to screen chemicals for possible cardiotoxicity.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiotoxicity; Doxorubicin; High content imaging; In vitro; Induced pluripotent stem cells; Mitochondria; Multi electrode array

Mesh:

Substances:

Year:  2017        PMID: 28456566     DOI: 10.1016/j.tiv.2017.04.023

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  13 in total

Review 1.  Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools.

Authors:  Li Pang; Zhichao Liu; Feng Wei; Chengzhong Cai; Xi Yang
Journal:  Arch Toxicol       Date:  2020-11-21       Impact factor: 5.153

2.  GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.

Authors:  S Tuuli Karhu; Sini M Kinnunen; Marja Tölli; Mika J Välimäki; Zoltán Szabó; Virpi Talman; Heikki Ruskoaho
Journal:  Arch Toxicol       Date:  2020-03-17       Impact factor: 5.153

Review 3.  hiPSCs in cardio-oncology: deciphering the genomics.

Authors:  Emily A Pinheiro; K Ashley Fetterman; Paul W Burridge
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

Review 4.  Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells.

Authors:  Huensuk Kim; Christoph Schaniel
Journal:  Front Immunol       Date:  2018-09-28       Impact factor: 7.561

Review 5.  Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity.

Authors:  Verena Schwach; Rolf H Slaats; Robert Passier
Journal:  Front Cardiovasc Med       Date:  2020-04-08

Review 6.  Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.

Authors:  Tatiana R Perry; Michelle L Roberts; Bipin Sunkara; Ragasnehith Maddula; Tyson McLeish; Jose Gomez; Julliette Lucas; David Rayan; Sahishnu Patel; Mingyu Liang; Zeljko J Bosnjak; Sherry-Ann Brown
Journal:  Curr Oncol Rep       Date:  2021-05-03       Impact factor: 5.945

7.  Method for selective ablation of undifferentiated human pluripotent stem cell populations for cell-based therapies.

Authors:  Tony Chour; Lei Tian; Edward Lau; Dilip Thomas; Ilanit Itzhaki; Olfat Malak; Joe Z Zhang; Xulei Qin; Mirwais Wardak; Yonggang Liu; Mark Chandy; Katelyn E Black; Maggie Py Lam; Evgenios Neofytou; Joseph C Wu
Journal:  JCI Insight       Date:  2021-04-08

Review 8.  Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity.

Authors:  Bin Bin Wu; Kam Tong Leung; Ellen Ngar-Yun Poon
Journal:  Int J Mol Sci       Date:  2022-02-09       Impact factor: 5.923

Review 9.  Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions.

Authors:  Nichanan Osataphan; Arintaya Phrommintikul; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  J Cell Mol Med       Date:  2020-04-26       Impact factor: 5.310

10.  Drug response analysis for scaffold-free cardiac constructs fabricated using bio-3D printer.

Authors:  Kenichi Arai; Daiki Murata; Shoko Takao; Anna Nakamura; Manabu Itoh; Takahiro Kitsuka; Koichi Nakayama
Journal:  Sci Rep       Date:  2020-06-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.